TABLE 2

Integrated β-cell secretory responses (insulin, C-peptide, and ISR) to oral glucose (50 g in 400 ml H2O) and adjustable (isoglycemic) intravenous glucose infusion (20% wt/vol), and calculated incretin effects (percent of the β-cell secretory response after oral glucose) in patients with chronic pancreatitis and secondary diabetes, patients with chronic pancreatitis and NGT, patients with type 2 diabetes, and healthy subjects

Patients with chronic pancreatitis and secondary diabetes*Patients with chronic pancreatitis and NGTPatients with type 2 diabetesHealthy subjects§
n (F/M)2/62/62/62/6
Integrated β-cell secretory responses
    Insulin (nmol/l per 4 h)
        Oral8.8 ± 1.7§10.9 ± 1.812.1 ± 2.318.4 ± 3.1
        Intravenous5.5 ± 1.33.0 ± 0.76.8 ± 1.85.2 ± 1.7
        Oral-intravenous3.4 ± 1.0§7.8 ± 1.5*5.3 ± 1.6§13.1 ± 3.0*
    C-peptide (nmol/l per 4 h
        Oral127 ± 20186 ± 37154 ± 28186 ± 21
        Intravenous87 ± 1362 ± 1496 ± 1488 ± 11
        Oral-intravenous40 ± 11*§124 ± 29*58 ± 1898 ± 20*
    ISR (nmol/l per kg)
        Oral687 ± 110698 ± 169783 ± 127649 ± 61
        Intravenous455 ± 61222 ± 53*511 ± 114305 ± 39
        Oral-intravenous166 ± 63*§476 ± 135*272 ± 68¶345 ± 55*
Relative incretin effects (%)
    Insulin36 ± 768 ± 7*44 ± 973 ± 6*
    C-peptide26 ± 767 ± 6*31 ± 952 ± 7*
    ISR31 ± 568 ± 6*34 ± 753 ± 5*
Average31 ± 468 ± 3*36 ± 660 ± 4*
  • Data are means ± SE. Significant differences (P < 0.05) between responses to oral glucose and isoglycemic intravenous glucose infusion within each group (¶) and significant differences (P < 0.05) in integrated β-cell secretory responses and incretin effects, respectively, between the four groups are indicated.

  • * Compared with patients with chronic pancreatitis and secondary diabetes.

  • Compared with patients with chronic pancreatitis and NGT.

  • Compared with patients with type 2 diabetes.

  • § Compared with healthy subjects.